Additional file 1 of Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study

Additional file 1: Table S1. Measurement values in depth of bone erosion at 6 months by HR-pQCT (full analysis set). Table S2. Change from baseline in bone erosion score and JSN score evaluated by X-ray (full analysis set). Table S3. Change from baseline in bone micro-architecture parameters evaluated by HR-pQCT, MRI, musculoskeletal ultrasound, and X-ray (full analysis set). Table S4. Actual measured values and percent changes from baseline in bone and cartilage biomarkers (full analysis set).